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Abstract
Cholesterol in milk is derived from the circulating blood through a complex transport process involving the mammary
alveolar epithelium. Details of the mechanisms involved in this transfer are unclear. Apolipoprotein-AI (apoA-I) is an
acceptor of cellular cholesterol effluxed by the ATP-binding cassette (ABC) transporter A1 (ABCA1). We aimed to 1)
determine the binding characteristics of 125I-apoA-I and 3H-cholesterol to enriched plasma membrane vesicles (EPM)
isolated from lactating and non-lactating bovine mammary glands (MG), 2) optimize the components of an in vitro
model describing cellular 3H-cholesterol efflux in primary bovine mammary epithelial cells (MeBo), and 3) assess the
vectorial cholesterol transport in MeBo using Transwell® plates. The amounts of isolated EPM and the maximal
binding capacity of 125I-apoA-I to EPM differed depending on the MG’s physiological state, while the kinetics of 3H-
cholesterol and 125I-apoA-I binding were similar. 3H-cholesterol incorporated maximally to EPM after 25±9 min. The
time to achieve the half-maximum binding of 125I-apoA-I at equilibrium was 3.3±0.6 min. The dissociation constant
(KD) of 125I-apoA-I ranged between 40–74 nmol/L. Cholesterol loading to EPM increased both cholesterol content and
125I-apoA-I binding. The ABCA1 inhibitor Probucol displaced 125I-apoA-I binding to EPM and reduced 3H-cholesterol
efflux in MeBo. Time-dependent 3H-cholesterol uptake and efflux showed inverse patterns. The defined binding
characteristics of cholesterol and apoA-I served to establish an efficient and significantly shorter cholesterol efflux
protocol that had been used in MeBo. The application of this protocol in Transwell® plates with the upper chamber
mimicking the apical (milk-facing) and the bottom chamber corresponding to the basolateral (blood-facing) side of
cells showed that the degree of 3H-cholesterol efflux in MeBo differed significantly between the apical and basolateral
aspects. Our findings support the importance of the apoA-I/ABCA1 pathway in MG cholesterol transport and suggest
its role in influencing milk composition and directing cholesterol back into the bloodstream.
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Introduction
Like other predominantly blood borne nutrients, cholesterol
crosses the mammary gland (MG) alveolar epithelium to enter
milk. In neonates, rapid growth and development of tissues and
organs necessitates high amounts of cholesterol, which are
mainly achieved in humans through breast-feeding or bottle-
feeding [1,2] (for review, see 3). However, elevated milk intake
from childhood onwards may influence circulating cholesterol
and represent a health risk [4,5]. For nutritional purposes, the
ability to regulate the content of cholesterol in milk might offer
significant benefits to people in terms of development and long-
term health. However, the molecular mechanisms that mediate
and control cholesterol transfer into alveolar milk are still
unclear.
An accumulating body of evidence from various studies
using cells other than mammary epithelial cells (MEC)
suggested that the ATP-binding cassette (ABC) transporter A1
(ABCA1) orchestrates cellular cholesterol export [6–8]. It is well
established that ABCA1 mediates the export of cholesterol to
apolipoprotein A-I (apoA-I) as part of an energy-dependent
high-density lipoprotein transport system [9,10]. Furthermore, it
has been demonstrated that apoA-I binds to both ABCA1 as
well as to high capacity binding sites on the plasma membrane,
i.e. phospholipid rich domains [11,12]. Studies performed in
fibroblasts or THP (human acute monocytic leukemia cell line),
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where plasma membrane has been fractionated and used for
immunoprecipitation, suggested the presence of ABCA1 in
non-raft, i.e. in detergent soluble domains of the plasma
membrane [13–15]. The apoA-I mediated cholesterol efflux is
impaired in fibroblasts from patients with mutated ABCA1
[16,17], confirming the significance of ABCA1 in regulating
cellular cholesterol homeostasis. It is established that
intracellular cholesterol accumulation is detrimental to cells and
accelerates foam cell formation, the hallmark of cardiovascular
diseases [18–20]. Whether this situation holds also true for
MEC that might utilize cholesterol as a precursor molecule in
the synthesis of sterol-based compounds entering the milk
composition is unclear.
In the MG relatively few studies were performed with regard
to the biochemistry of binding function, in contrast to
characterizational studies, that simply identified the presence of
ABC transporters by gene expression analysis or
immunohistochemistry [21–24]. ABCA1 expression was
demonstrated in the epithelium of normal and neoplastic
human breast tissues [22]. The expression of ABCA1, ABCG1
and ABCA7 was shown in the alveolar and ductal epithelium as
well as in mammary adipocytes [23]. More generally, ABC
transport proteins, in particular ABCA1, showed differential
expression in MEC and stromal cells of lactating and non-
lactating bovine MG tissues with a more pronounced protein
expression in MEC [23]. In MEC, ABCA1 protein was identified
in the cell membrane with often apical accentuation [23]. The
localization of ABCA1 in the alveolar epithelium of the bovine
MG strongly suggests its importance in MG cholesterol
homeostasis. On the other hand, the presence of apoA-I, the
key acceptor of cholesterol exported by ABCA1, has been
demonstrated in bovine milk [25,26]. Therefore, an implication
of the apoA-I/ABCA1 pathway as cholesterol transport
mechanism relevant for milk composition is possible, but has
not been reported.
To get more insights about the role of the apoA-I/ABCA1
pathway in cholesterol transport in the MG, we sought to
establish and validate a cell-based assay system capable of
characterizing the kinetic determinates of cholesterol transport
and efflux. The current study extends our previous work [23,24]
by establishing a model using ex vivo collected MG tissue to
define binding characteristics of components of the high-
density lipoprotein (i.e. apoA-I and cholesterol), and to
establish criteria and validate a cell-based cholesterol efflux
assay in MEC. The binding parameters of 125I-apoA-I and of 3H-
cholesterol were determined during saturation and competition
binding assays with enriched plasma membrane vesicles
(EPM) isolated from lactating and non-lactating bovine MG
tissues. Herein, we describe the development and validation of
an efficient and significantly shorter cholesterol efflux protocol
that can be used for functional investigations in cultured MEC.
Consequently, by applying this functional assay to MEC in the
Transwell® system the present study demonstrates vectorial
cholesterol transport in primary MEC and thereby highlights the
importance of the apoA-I/ABCA1 pathway in cholesterol
transport in the MG.
Materials and Methods
Ethics statement
Not applicable.
Reagents and materials
Chloramine-T trihydrate, apoA-I prepared from human
plasma, cholesterol, Dulbecco’s Modified Eagle Medium
(DMEM) Nutrient Mixture F-12 Ham, and RPMI medium were
purchased from Sigma-Aldrich (St. Gallen, Switzerland). EGTA,
HEPES, probucol, uranyl acetate, and sodium pyrosulfite were
obtained from Fluka (Buchs, Switzerland). The protease
inhibitor cocktail (complete EDTA-free) was purchased from
Roche (Basel, Switzerland). The BCA Protein Assay Reagent
kit was purchased from Pierce (Rockford, IL). The Amplex Red
Cholesterol Assay kit, antibiotics, and antimycotics were
purchased from LubioScience (Luzern, Switzerland).125 I
(specific activity ~17Ci/mg) and 1α, 2α [N]-3H-cholesterol
(specific activity 53Ci/mmol, in ethanol) were purchased from
PerkinElmer (Schwerzenbach, Switzerland). Glass fiber filters
(MN GF-3) were obtained from Macherey-Nagel (Oensingen,
Switzerland). Primary bovine mammary epithelial cells (MeBo)
were isolated and characterized as previously described [27]
by the donator Prof. Craig Baumrucker from Penn State
University (Pennsylvania, USA); RAW264.7 cells (murine
macrophages) were of commercial origin (ATCC number:
TIB-71) but were gifted by Prof. Jürg Gertsch from the
University of Bern (Switzerland).
A: Studies with ex vivo MG tissues
Tissue collection.  MG tissue samples were obtained from
a total of six healthy dairy cows at the slaughterhouse Marmy
Viandes en Gros SA (Estavayer-Le-Lac, Switzerland) from
which we obtained the permission to use these animal samples
for scientific purposes. These animals were part of the routine
slaughter by stunning as authorized by the Swiss Law of
Animal Protection (RS 455), and have not been subjected to
previous animal experimentation. Three cows were in the
lactating and three in the non-lactating state. Tissues were
collected immediately after slaughter. To identify the presence
(or absence) of milk, and to subsequently classify the MG as
lactating or non-lactating, a visual inspection of the MG incision
was carried out. MG tissues were collected into ice-cold 50mM
Tris HCl assay buffer (pH 7.4) containing 6mM MgCl2 and 1mM
EGTA and supplemented with a protease inhibitor cocktail.
Plasma membrane preparation — The procedure for
isolation of EPM was as previously described [28–30], with
minor modifications described in [31]. All procedures were
carried out at 4°C. In brief, MG was first minced into small
pieces in chilled assay buffer. Tissues were homogenized for 2
min with an Ultra-Turrax homogenizer T25 (Janke & Kunkel,
Staufen, Germany). The homogenate was centrifuged at 800 ×
g for 10 min followed by centrifugation of the supernatant at
10,000 × g for 10 min. The resulting supernatant was
centrifuged at 100,000 × g for 1h; the obtained microsomal
pellet was suspended in ice-cold assay buffer by a motor-
driven Glass-Teflon homogenizer to obtain a mixed (or crude)
Cholesterol transport in mammary gland
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membrane suspension. The latter was mixed with MgCl2 (final
concentration 12mM) under constant stirring for 30 min, and
then centrifuged at 3000 × g for 15 min. In this study, MgCl2
was used instead of CaCl2 as described by Lin and colleagues
[31], because millimolar concentrations of calcium might alter
the overall structure and integrity of membranes [32,33].
Following MgCl2 treatment, the supernatant containing
plasmalemma was centrifuged at 48,000 × g for 1h. The pellet
was re-suspended in assay buffer, and the resulting
suspension, i.e. EPM was stored at -80°C until used. The
enrichment of plasma membrane preparations was confirmed
by Western blot analysis of ABCA1, where a stronger ABCA1
reactivity in EPM as compared to the crude membrane
preparation was observed (unpublished data).
Transmission electron microscopy.  Fixation and
processing were carried out as described by 34. Ultrathin (~ 80
nm) sections of embedded samples were cut with a
ultramicrotome UC6 Leica Microsystems (Vienna, Austria) and
contrasted with lead citrate and uranyl acetate. The stained
sections were inspected with a transmission electron
microscope CM12 Philips (Eindhoven, Netherland) equipped
with a digital camera Morada, Soft Imaging System (Münster,
Germany) and image analysis software (iTEM) at various
magnifications.
Biochemical analyses.  The protein concentration of EPM
suspensions was determined with a BCA kit. The cholesterol
content of the EPM and the cell lysate as well as the
cholesteryl ester content of the cell lysate (see section B
below) were measured with Amplex Red® Cholesterol Assay
kit. All analyses were performed following the manufacturers’
protocols.
Radiolabeling of substrates.  ApoA-I was iodinated with 125I
by using the chloramine-T method [35]. In brief, apo-AI was
diluted in phosphate buffer and then mixed with 0.5mCi of 125I.
The iodination reaction was initiated by adding chloramine-T
trihydrate to the mixture, and was stopped 30 sec later with
sodium pyrosulfit. The reaction mixture was filtrated with
Sephadex G-200 superfine Pharmacia Fine Chemicals
(Upssala, Sweden) poured onto a 1.6×33cm column for
desalting and removal of free 125I in a buffer consisting of 10
mM Tris-HCl, 100 mM KCl, 1mM sodium azide, pH 7.4 that
was supplemented with 2mg/ml of bovine serum albumin (BSA)
to prevent the loss of the protein due to unspecific binding to
Figure 1.  Transmission electron microscopy of mammary gland (MG) enriched plasma membrane vesicles (EPM).  A:
Representative electron micrograph of EPM from lactating MG at 31’000 × magnification. Arrows depict single vesicles. B: The
bilayer structure of the EPM from the same lactating MG at 230’000 × magnification. Electron micrographs of EPM isolated from
non-lactating MG (not shown) were similar to that of lactating tissue.
doi: 10.1371/journal.pone.0070407.g001
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the column [36]. The specific activity of 125I-apoA-I was
41µCi/µg protein.
Binding studies and procedures.  Binding assays were
performed with working solutions of 3H-cholesterol and 125I-
apoA-I that were prepared by diluting their respective stock
solutions in Tris-HCl assay buffer. If not otherwise indicated, all
binding assays were performed with a fixed amount (100µg) of
EPM protein at 37°C. The final concentration of ethanol in the
binding assay mixture was < 0.1%.
The association binding (or incorporation) of 3H-cholesterol
(1nM and 10nM) and of 125I-apoA-1 (10nM) to EPM was
determined by incubating the assay mixture for different
durations up to 48h. To study the dissociation binding of 125I-
apoA-I, the radiolabel (10nM) was first incubated with EPM
until the equilibrium was reached; then 1.4µM of unlabeled
apoA-I was added to the mixture followed by different
incubation times. The saturation binding of 125I-apoA-I was
analyzed by measuring the binding of increasing
concentrations of radiolabel (range 0.5 to 55 nM) to EPM for 15
min in the presence and absence of 1.4µM unlabeled apoA-I.
To verify that 125I-apoA-I binding (10nM) can be inhibited, its
binding to EPM for 15 min in the presence and absence of
1.4µM unlabeled apoA-I was measured and compared. In
addition, the inhibition binding of 125I-apoA-I by increasing
concentrations (10-13 to 10-4M) of the ABCA1 inhibitor probucol
[37,38], used as a complex with BSA [38], was determined.
Furthermore, the likely interference of cholesterol on apoA-I
binding was analyzed by measuring the binding of 10nM 125I-
apoA-I to EPM for 15 min in the presence and absence of
preloading with 1.6mM cholesterol for 30 min at 37°.
All binding assay mixtures were incubated under constant
shaking, and reactions were stopped by adding 2ml of chilled
assay buffer (the same as for tissue collection). The mixtures
were then filtrated through glass fiber filters MN GF-3
(Macherey-Nagel, Oensingen, Switzerland) by using a vacuum
filtration manifold (Hölzel, Wörth, Germany). Prior to use, the
filters were equilibrated in Tris-HCl assay buffer supplemented
with 2 mg/ml (w/v) BSA.125 I-activity and 3H-activity were
measured with a γ-counter and β-counter, respectively
(Kontron, Schlieren, Switzerland). The GraphPad software
program (GraphPad Software, Inc., San Diego, CA) was used
for curve fitting and for the determination of binding
characteristics of 125I-apoA-I and 3H-cholesterol.
B: Cell culture studies
Cell culture.  MeBo cells originating from two dairy cows at
late lactation have been previously characterized [27,39]. Cells
were incubated at 37°C with 5% CO2 in T75 polystyrene culture
flasks. They were grown in complete DMEM-F12 medium
supplemented with 10% fetal bovine serum and 1% antibiotics/
antimycotics. For cell splitting and passaging, 0.05% trypsin
EDTA solution was used. To assure a similar differentiation
state, all efflux experiments were performed with MeBo cells
within two passage numbers originating from the same batch.
Throughout the experiments the cell density was approximately
of 200’000 cells per well in 12-well plates. The confluence prior
to the start of the cholesterol efflux assay was approximately
90%.
Cholesterol efflux.  The cholesterol efflux assay was
adapted from a previously published procedure for RAW264.7
Figure 2.  Time-dependent 3H-cholesterol incorporation to mammary gland (MG) enriched plasma membrane vesicles
(EPM).  The figure illustrates representative kinetics of incorporation of 1nM (●) and 10nM (■) 3H-cholesterol into EPM (100µg)
isolated from lactating MG tissues. Data represent the means of three independent experiments performed in triplicates. The
incorporation reaction was incubated at 37°C using glass tubes coated with bovine serum albumin. The radioactivity of the filter was
measured using a β-counter. No difference was found between lactating and non-lactating MG.
doi: 10.1371/journal.pone.0070407.g002
Cholesterol transport in mammary gland
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cells [40]. Prior to using the assay in MeBo cells the protocol
was tested in RAW264.7 cells cultured in complete RPMI
medium. Based on the binding characteristics of cholesterol
and apoA-I obtained from the ex vivo investigations (see
Results, section A), MeBo cells growing in complete DMEM-
F12 medium on the plastic surface were loaded for 0.5, 1 and
24h with 3H-cholesterol (1µCi/ml, dissolved in ethanol). 3H-
cholesterol uptake by cells was estimated by relating the
remaining 3H-activity in the medium (M1) to the initially loaded
radioactivity (uptake evaluation 1). After cholesterol loading
cells were equilibrated for 0, 0.5, 1 and 18h in serum-free
DMEM-F12 medium. Cholesterol efflux was initiated by adding
the cholesterol acceptor apoA-I to the cell medium; the efflux
medium (M2) was collected after apoA-I incubation for 0.25, 1
and 4h. After removal of the efflux medium the plates were
frozen at -20 °C for 30 min. Then, dPBS was added and the
plates were shaken for 30 min at room temperature prior to
lysate collection. The collected M1 and M2 samples were
centrifuged for 10 min to get rid of cell debris. An equal volume
of M1, M2, and cell lysate was transferred into scintillation vials
and mixed with 4ml of the scintillation liquid for β-counting.
The percentage of 3H-cholesterol efflux was calculated by
relating the radiolabel in M2 to the sum of radiolabel in M2 and
in cell lysate. ApoA-I mediated cholesterol efflux was obtained
by subtracting the value of the efflux measured in the absence
of apoA-I from that in the presence of apoA-I. The cholesterol
uptake was furthermore evaluated by calculating the sum of the
Figure 3.  Binding of 125I-apoA-I to mammary gland (MG) enriched plasma membrane vesicles (EPM).  A: Representative
graph of 125I-apoA-I binding (5nM) to increasing concentrations of EPM (range 0.25 to 2 mg/ml) at 37°C (●) and 4°C (□). Dose-
dependent 125I-apoA-I binding was only observed at 37°C. B: Representative curves of 125I-apoA-I binding (10nM) kinetics at 37°C to
a fixed amount (100µg) of EPM. For the association binding of 125I-apo-A1 (▲), the maximal binding (saturation) was reached after
10 min incubation at 37°C, and was expressed as 100% binding. For the dissociation binding (○), 125I-apoA-I binding was incubated
for 15 min at 37°C. Then, excess amounts (40µg/ml) of cold apoA-I were added and the dissociation of 125I-apoA-I was evaluated at
indicated incubation times. Data shown are from lactating MG. Similar curves were obtained for non-lactating MG. C: Saturation
binding curve of 125I-apoA-I (range 2 to 56nM) to a fixed amount (100µg) of EPM from lactating (▲) and non-lactating (●) MG
tissues. The reaction was incubated for 15 min at 37°C. D: Competition binding of 125I-apoA-I to a fixed amount of EPM (100µg) from
lactating and non-lactating MG tissues by probucol-BSA (●) and BSA (◊). The probucol-BSA complex was prepared as described by
others (37). The reaction was incubated for 15 min at 37°C. All other details of the binding procedure were as described in Figure 2
except that the radioactivity of the filters was measured with a γ-counter. All data are expressed as means ± SD.
doi: 10.1371/journal.pone.0070407.g003
Cholesterol transport in mammary gland
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radiolabel in the cell lysate and in M2, and related to the initially
loaded radioactivity (uptake evaluation 2).
Vectorial cholesterol efflux using the Transwell®
system.  To distinguish apical from basal cholesterol transport,
MeBo cells were cultured in double chamber Transwell® plates.
Cells were grown to confluence on six-well cell culture
Transwell® plates (BD Biosciences, La Pont de Claix, France)
in DMEM-F12 medium supplemented with 10% FBS and 1%
antibiotics/antimycotics added to the top (apical) and bottom
(basal) chambers. Cells were grown for approx. five days until
reaching confluence. The formation of a tightly sealed polarized
cell monolayer at confluence was verified by measuring the
resistance and subsequently calculating the trans-epithelial
electrical resistance (TEER) in cell-loaded and cell-free
Transwell® membranes with the Millicell-ERS Volt-Ohm meter
(Millipore, MA, USA) according to [41]. Lucifer Yellow dilithium
salt (Sigma, Switzerland), a fluorescent dye mainly transported
across polarized cells in a paracellular fashion, was used to
Figure 4.  Kinetics of 3H-cholesterol transport in primary bovine mammary epithelial (MeBo) cells.  A: Comparative uptake
(●) and efflux (▲) of 3H-cholesterol by MeBo cells growing as a monolayer in DMEM-F12 medium supplemented with 10% fetal
bovine serum and 1% antibiotics/antimycotics. Cholesterol efflux was performed in the presence of 10µg/ml apoA-I (details see
Materials and Methods). The cholesterol uptake was calculated either based on the amount of radiolabel disappearing from the
medium (evaluation 1) or on the sum of the radiolabel measured in the cell lysate and efflux medium (evaluation 2). Both values
were related to the initially loaded amounts of radiolabel that was defined as 100%. The arrow depicts the inversion point that is the
incubation time where cholesterol uptake and efflux are in apparent equilibrium. It represents a threshold beyond which the
availability of 3H-cholesterol for efflux becomes markedly reduced in favor of increasing intracellular compartmentalization.” B:
Cholesteryl ester content of the cell lysate. Cholesteryl esters were measured with the Amplex Red® assay kit according to the
manufacturer’s instructions. All experimental details were as described in section A. C: Time-dependent saturation curve of apoA-I
mediated efflux. Cells were loaded with cholesterol for 0.5h (●), 1h (■), and 24h (▲). Details for cell equilibration were as described
in section A. Please note that in contrast to Figure 4A, the background efflux measured in the absence of apoA-I was recorded, and
subtracted from the total efflux measured in the presence of 10µg/ml of apoA-I. D: Regulation of apoA-I mediated efflux in MeBo
cells. Cells were loaded with 3H-cholesterol (1µCi/ml) in complete DMEM-F12 medium supplemented with 10% fetal bovine serum
and 1% antibiotics for 24h. Cells were equilibrated for 18h in serum-free medium followed by the efflux in the presence of apoA-I
(10µg/ml) for 4h (see Materials and Methods for additional details). Cells were treated with probucol, an inhibitor of ABCA1,
throughout the efflux time. All data are expressed as means ± SD of three independent experiments performed in triplicates.
doi: 10.1371/journal.pone.0070407.g004
Cholesterol transport in mammary gland
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e70407
monitor the tight junction integrity [42]. The apparent
permeability (Papp) through the cell-loaded and cell-free
Transwell® membranes was calculated as described by others
[43]. Fluorescence detector Flex Station II plate reader
(Molecular Devices GmbH, Biberach, Germany) was used to
measure fluorescence at an excitation and emission
wavelength of 425nm and 530nm, respectively. The
appearance of fluorescent Lucifer Yellow is proportional to the
amount of the dye crossing the MEC monolayer. After loading
to the apical and basal compartment, respectively, Lucifer
Yellow was measured in the opposite chamber. The procedure
for the efflux was as described above (loading 1h, equilibration
1h, efflux 1h), except that apoA-I was loaded to the apical and
the basal chambers.
Statistical analysis
All statistical analyses were performed with non-parametric
tests using GraphPad Prism (San Diego, CA) software. Protein
and cholesterol content of EPM, maximal binding capacity of
125I-apoA-I, determinants of apoA-I mediated efflux and
vectorial apoA-I mediated 3H-cholesterol efflux in MeBo cells
were analyzed for statistical difference using the Mann-Whitney
test; cholesterol uptake and efflux at various time points were
compared using the Kruskal-Wallis test. The level of
significance was set at P < 0.05.
Results
The unequivocal reproduction of lactating and non-lactating
states of the MG in vitro is difficult due to the complexity in the
regulation of pregnancy-lactation cycle as well as to factors
inherent to the cell culture. Therefore, a two-step analytical
approach combining ex vivo MG tissues and culturing of MEC
had been chosen to ascertain both the suitability of the defined
cholesterol efflux conditions for functional studies with primary
MEC and the relevance of the apoA-I/ABCA1 pathways in
cholesterol transport in the MG.
A: Studies using ex vivo MG tissues
Isolation and identification of EPM — The amounts of
isolated EPM differed depending on the physiological stage of
the MG (Table 1). The total protein levels in EPM were higher
in lactating than in non-lactating MG tissues. In contrast,
cholesterol content of EPM was higher in non-lactating MG
than in lactating MG tissues (Table 1). The isolated EPM
vesicles were inspected by electron microscopy (Figure 1).
Figure 1A shows a representative image of EPM vesicles
derived from lactating MG tissues (31’000 x magnification). The
insert (Figure 1B) depicts a bilayer structure of the same EPM
sample. Similar images were obtained for EPM isolated from
non-lactating MG (not shown).
3H-cholesterol incorporation to EPM — The incorporation of
3H-cholesterol to EPM reached a plateau after 25 ± 9 min both
when 1nM or 10nM 3H-cholesterol was used (Figure 2). The
average percentage of 3H-cholesterol incorporation was
markedly decreased at the 10 fold higher concentration of 3H-
cholesterol (Figure 2), with average values of 92 ± 6% (1nM)
as compared to 61 ± 8% (10nM).
Figure 5.  Vectorial 3H-cholesterol transport in primary
bovine mammary epithelial (MeBo) cells. A: Time-
dependence of the trans-epithelial electrical resistance of
MeBo cells grown as monolayer in Transwell® tissue
culture plates. MeBo cells were exposed to DMEM-F12
medium supplemented with 10% fetal calf serum and 1%
antibiotics/antimycotics that was added to the apical and
basal chambers.  Resistance was measured according to the
manufacturer’s instructions in quadruplicates of >12 wells.
Trans-epithelial electrical resistance was calculated according
to [41]. B: Vectorial apoA-I mediated 3H-cholesterol efflux in
MeBo cells. The experiment was performed according to the
optimized protocol (loading 1h, equilibration 1h, efflux 1h). All
other details of the procedure were as described in Figure 4B.
ApoA-I was added either to the apical (A) or to the basal (B), or
to both chambers (A’, B’). ApoA-I mediated cholesterol efflux
was calculated separately for the apical and the basal chamber
by subtracting the background efflux. All data are expressed as
means ± SD of triplicates measurements.
doi: 10.1371/journal.pone.0070407.g005
Cholesterol transport in mammary gland
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Linearity of 125I-apoA-I binding — The binding of 125I-apoA-I at
37°C increased with augmenting amounts of EPM (R2 = 0.98)
independent of the physiological state of the MG (Figure 3A). In
contrast, no increase of 125I-apoA-I binding (R2 = 0.22) was
observed when the reaction was incubated at 4°C (Figure 3A).
Results illustrated in Figure 3A are representative data derived
from non-lactating MG tissues. Similar data were obtained for
lactating MG (not shown).
Association and dissociation binding of 125I-apoA-I.  The
binding of 125I-apoA-I reached maximal values after 10 min
incubation at 37°C (Figure 3B), and did not change with a
prolonged incubation period. Half maximal 125I-apoA-I
association binding to EPM was 3.3 ± 0.6 min (Figure 3B)
regardless of the physiological state of the MG tissue.125 I-apoA-
I dissociation binding was 25 ± 3 min (Figure 3B). A fraction of
125I-apoA-I binding ranging between 30–36% could not be
inhibited by excess amounts of cold apoA-I (Figure 3B). The
association and dissociation of 125I-apoA-I did not change with
an incubation period until 48h (data not shown).
Saturation binding of 125I-apoA-I.  Although the binding of
125I-apoA-I did not clearly saturate within the range of
concentrations used, apparent KD and maximal binding
Table 1. Biochemical characteristics of mammary gland
derived enriched plasma membranes (EPM).
Traits Lactating tissues Non-lactating tissues
EPM proteins1   
mg per g MG tissue 1.32 ± 0.28a 0.77 ± 0.27b
Cholesterol content2   
µmol per mg EPM protein 0.20 ± 0.01 0.31 ± 0.12
µmol per g MG tissue 0.26 ± 0.02 0.23 ± 0.09
125I-apoA-I binding3   
Bmax (pmol/mg protein) 5.87 ± 1.88b 11.5 ± 1.19a
KD (nmol/L) 40 ± 24 74 ± 12
% inhibition by cold apoA-I 71.4 ± 8.29 79.2 ± 2.59
% increase by cholesterol 64 ± 24 40 ± 23
All results are based on enriched plasma membranes (EPM) prepared and
processed as described in Materials and Methods. Data are presented as mean ±
SD (n=3).
1. Protein concentrations of EPM were measured with the BCA protein assay kit
2. Cholesterol content of EPM was determined by using Amplex Red Cholesterol
Assay kit following the manufacturer’s instructions.
3. All binding reactions were incubated for 15 min at 37°C under constant shaking.
The maximal binding capacity (Bmax) and the dissociation constant (KD) of 125I-
apoA-I binding were measured during saturation binding of 125I-apoA-I (range 2 to
56nM) to 100µg EPM as presented in Figure 3B. The specific binding of 125I-apoA-I
was obtained by subtracting binding in the presence of cold apoA-I (1.4µM) from
that in the absence of cold apoA-I. The percentage inhibition of 125I-apoA-I binding
(10nM) by cold apoA-I was obtained by relating the binding of 125I-apoA-I in the
presence of cold apoA-I to the binding in the absence of cold apo-A1, which was
defined as 100%.
The effect of cholesterol loading on 125I-apoA-I binding was determined by
comparing 125I-apoA-I binding to EPM (100µg) in the presence and absence of
preloading with 1.6mM cholesterol for 30 min at 37°C.
Mean values with different superscript letters (a b within the row are statistically
different (P < 0.05).
capacity (Bmax) can be calculated from the fitting curve,
assuming saturation at higher doses. The average Bmax values
of 125I-apoA-I binding derived from the fitting curve of the three
experiments differed between non-lactating (95% confidence
interval: 1.6, 21) and lactating MG tissues (95% confidence
interval: 2, 10) (Figure 3C and Table 1). In both cases, KD
values derived from 125I-apoA-I saturation binding curves were
in the nanomolar range (Table 1).
Competition binding of 125I-apoA-I.  The binding of 125I-
apoA-I was inhibited by excessive amounts of unlabeled apoA-I
in EPM from both lactating and non-lactating MG tissues (Table
1). Furthermore, increasing concentrations of probucol-BSA
(10-13 to 10-4M) inhibited 125I-apoA-I binding at micromolar
concentrations in lactating and non-lactating MG tissues
(Figure 3D). Binding data were fitted to a one-site inhibition
model (Figure 3D) and EC50 values derived from the fitting
curve of lactating (R2 = 0.77) and non-lactating (R2 = 0.81)
EPM were 13 ± 10 and 0.4 ± 0.03 µM, respectively. BSA alone
did not inhibit 125I-apoA-I binding (Figure 3D).
Interference of cholesterol with 125I-apoA-I
binding.  Loading of EPM with 1.6mM cholesterol (dissolved in
100% ethanol) markedly increased 125I-apoA1 binding in
lactating and non-lactating MG tissues (Table 1). Additional
investigations showed that cholesterol loading markedly
increased the EPM cholesterol content (unpublished data).
B: Cell culture studies
Taking into account the binding characteristics of 125I-apoA-I
and 3H-cholesterol to EPM obtained in the ex-vivo
investigations (see Results, section A), we optimized the
cellular cholesterol efflux in MeBo cells with regard to
incubation, equilibration and efflux times. The initial protocol for
cellular cholesterol efflux was based on RAW264.7 cells
(murine macrophages) and yielded efflux values of 10.6 ±
2.27% for 4h, i.e. similar to the results reported by the authors
[40].
Uptake profile of 3H-cholesterol by MeBo.  As described in
Materials and Methods cholesterol uptake was calculated in
two different ways: firstly estimated from the amount of
radiolabel disappearing from the medium (M1, uptake
evaluation 1) and secondly calculated as the sum of the
radiolabel measured in the cell lysate and efflux medium M2
(uptake evaluation 2). Both calculation methods showed a
steady increase of 3H-cholesterol uptake with incubation time
(Figure 4A). The inversion point shows the cholesterol
incubation time where uptake and efflux are apparently in the
equilibrium (Figure 4A). In parallel, intracellular cholesteryl
esters accumulated with increasing incubation times (Figure
4B).
The percentage of uptake was lower when cells were loaded
with 3H-cholesterol for 0.5h than for 24h (Table 2). However,
the percentage of uptake did not change between cells loaded
for 0.5h and 1h, and for 1h and 24h, respectively (Table 2).
3H-cholesterol efflux — ApoA-I mediated 3H-cholesterol efflux
was unchanged when the apoA-I incubation time was 1 or 4h
(Table 2). An apoA-I incubation time of only 2 min significantly
decreased 3H-cholesterol efflux as compared to all other time
points. However, there were no differences in cholesterol efflux
Cholesterol transport in mammary gland
PLOS ONE | www.plosone.org 8 July 2013 | Volume 8 | Issue 7 | e70407
between apoA-I incubation times of 15 min and 1h (Table 2).
The apoA-I mediated cholesterol efflux in MeBo cells showed
always a saturable pattern (Figure 4C).
Given that the probucol-BSA complex inhibited 125I-apoA-I
binding to ex vivo isolated EPM in µmolar concentrations, the
effect of probucol treatment (10µM) on cellular cholesterol
efflux was analyzed. ApoA-I mediated 3H-cholesterol efflux was
reduced by 70.4% in probucol treated as compared to control
cells (Figure 4D).
Vectorial 3H-cholesterol efflux.  The evaluation of TEER
indicated that MeBo cells formed a tightly sealed monolayer
after approx. 5-7 days of culture in complete medium (Figure
5A). In addition, the permeability test with Lucifer Yellow
confirmed the presence of a tightly sealed monolayer (Papp<
10-6 cm/s). Using the optimized efflux protocol (loading 1h,
equilibration 1 h, efflux 1h), apoA-I mediated cholesterol efflux
occurred at both the apical and basal side of the MeBo
monolayer, but was more pronounced at the basal side (Figure
5B). Simultaneous loading of apoA-I to both chambers gave
similar results as individual loading to the apical and
basolateral compartment, respectively (Figure 5B, A’ and B’).
The significantly higher cholesterol efflux at the basolateral side
was also confirmed when the conventional efflux protocol
(loading 24h, equilibration 18 h, efflux 4h) was applied (data
not shown).
Discussion
The present study shows that EPM isolated from ex vivo MG
tissues are suitable for defining the binding characteristics of
apoA-I and cholesterol and that those criteria are useful for
designing optimal cholesterol efflux assay conditions applicable
Table 2. Comparative 3H-cholesterol uptake and efflux in
primary bovine mammary epithelial cells.
 Incubation time for cholesterol or apoA-I
Traits 2 min 15 min 30 min 1h 4h 24h
Uptake1
(%) n.d. n.d. 17 ± 8
b 21 ± 8ab n.d. 30 ± 9a
Efflux2 (%) 0.17 ±0.10c
1.32 ±
0.64b n.d.
1.91 ±
0.65ab
2.15 ±
0.88a n.d.
Data (mean ± SD) are representative of three independent experiments performed
in triplicates. Mean values with different superscript letters (a b c within the row are
statistically different (P <0.05).
1 shows the uptake of 3H-cholesterol after loading cells with 1µCi/ml of 3H-
choelsterol for 30 min, 1h and 24h. The uptake is indirectly calculated by
measuring the remaining radioactivity after each incubation time. The initially
loaded activity was defined as 100%.
2 shows apoA-I mediated efflux that was obtained by subtracting the background
efflux (in the absence of apoA-I) from total efflux (in the presence of 10µg/ml apoA-
I). Cells were loaded with 3H-cholesterol for 30 min, 1h and 24h in complete
DMEM-F12 medium and equilibrated for 18h in serum-free DMEM-F12 medium.
Pooled data of apoA-I mediated efflux are shown as no differences were observed
between different 3H-cholesterol loading times (30 min, 1h and 24h).
n d: not determined.
to primary MEC. The binding characteristics of apoA-I and
cholesterol were tested in EPM extracted from MG tissues (i.e.
EPM originating from various cell types) at native lactating and
non-lactating states to verify that the finally defined efflux
conditions can be translated to pure MEC independent of their
naturally or experimentally induced physiological state
(lactating or non-lactating). In this context it is worthwhile to
note that the physiological interpretation of the comparison
between lactating and non-lactating MG was beyond the scope
of the present study.
The identification of 125I-apoA-I binding to EPM isolated from
lactating and non-lactating tissues supports the importance of
apoA-I mediated cholesterol transport in the MG. The binding
of 125I-apoA-I to EPM was fast and temperature sensitive
because it reached the plateau after 10 min incubation, and
occurred in a concentration dependent manner at 37°C but not
at 4°C. These findings are in agreement with previously
reported apoA-I binding data [44,45]. In the current study, the
time to achieve the half-maximum binding of 125I-apoA-I at
equilibrium was 3.3±0.6 min, whereas the half-time of
dissociation binding was 25 min. The data reported here
corroborate those published by others in 293 cells using cross-
linking assays [46], suggesting that the binding properties of
iodinated apoA-I were similar between the two studies. The fact
that 125I-apoA-I binding reached a plateau after only
approximately ten minutes suggests that an apoA-I incubation
time of a few minutes, instead of several hours as frequently
used in efflux experiments [7], is sufficient for cholesterol efflux
in primary MEC.
Interestingly, the binding of 125I-apoA-I to EPM was displaced
at µmolar concentrations by probucol, an inhibitor of ABCA1
[37,38,47]. Accordingly, the apoA-I mediated cholesterol efflux
by MeBo cells was strongly suppressed in cells treated with
probucol used at comparable concentrations. Taken together,
these findings support a role of the apoA-1/ABCA1 pathway in
cholesterol transport in the MG.
In the current study the binding of 125I-apoA1 to EPM was
increased when the latter was loaded with millimolar
concentrations of cholesterol. On the other hand, cholesterol
loading increased the EPM cholesterol content. Taken together
this may suggest a potential role of cholesterol as a
“modulator” of apoA-I binding. It may be speculated that loaded
cholesterol contributes to the formation of additional lipid-rich
domains to which apoA-I binds. In support of this assumption,
we found that the maximal binding of 125I-apoA-I (normalized to
EPM protein) tended to be greater in non-lactating MG tissues
containing higher levels of cholesterol than in lactating MG
tissues with lower cholesterol content. Interestingly, if the
binding data are normalized to the amount of EPM cholesterol,
the maximal binding capacity of 125I-apoA-I was similar between
lactating and non-lactating MG (unpublished data). In the
current study a portion of 125I-apoA-I binding could not be
displaced by native apoA-I. Similar findings have been
previously reported in other studies where it was speculated
that the presence of iodine in the apoA-I molecule may cause
changes in the phospholipid binding properties [45] [48]. In the
present study it was not determined if iodine incorporation
occurred at the region where apoA-I binds to ABCA1.
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Nonetheless, as discussed above, the half-time of association
and dissociation of 125I-apoA-I binding reported here were
similar to that determined by others.
In the present study the initially determined binding
characteristics of 3H-cholesterol and 125I-apo-AI in the ex vivo
MG model served to optimize the cholesterol efflux conditions
in MEC. The rationale for the optimization was as follows: 1)
3H-cholesterol incorporation to EPM reached the plateau after
less than 1h incubation at 37°C whereas 3H-cholesterol uptake
by MeBo cells steadily increased with incubation time. These
results imply that EPM per se have a limited cholesterol loading
capacity that might be reached relatively fast. 2) The inversion
point was observed in cells loaded for approximately 80 min.
This point seemed to be a threshold beyond which the
availability of 3H-cholesterol for efflux becomes markedly
reduced in favor of increasing intracellular
compartmentalization likely in the form of cholesteryl esters.
Based on that, a preloading step lasting for 1 h could be
sufficient for the cholesterol efflux assay in MEC. A similar
loading time has been utilized for efflux assay in J774 cells
using BODIPY-cholesterol [49]. 3) The inversion point showed
an apparent equilibrium between cholesterol efflux and uptake
processes. The comparison of cell equilibration times lasting 0,
0.5, 1, and 18h suggested that an equilibration time of 1h is
optimal for cholesterol efflux in MeBo cells. 4) The
concentration of apoA-I typically used for the efflux (10µg/mL)
is more than 4 times its measured KD, and is therefore high
enough to favor maximal apoA-I activity.
In summary, the herein optimized cholesterol efflux protocol
for MeBo cells includes loading with 3H-choleserol (1µCi/ml) for
1h, cell equilibration in serum-free medium for 1h, and
cholesterol efflux in the presence of 10µg/mL apoA-I for 1h.
This protocol allows performing the cholesterol efflux assay
within a time period of 3h instead of 46 h needed with the
protocol initially published by others [40]. However, the
currently optimized protocol in MeBo cells did not show the
same efficiency in RAW264.7 cells. We observed that both
cholesterol uptake and efflux in RAW264.7 were higher when
cells were loaded for 24h than for 1h. In MeBo cells cholesterol
uptake was higher when cells were loaded for 24h than for 1h,
but contrary to RAW264.7, the efflux levels remained similar
(unpublished data). This might be due to differences related to
cholesterol processing in RAW264.7 and MEC. Another
limitation of the developed short cholesterol protocol might
arise when specific protein modulating agents (e.g. ABCA1
inducers or inhibitors) are applied which may need longer than
one hour for exerting measurable effects on protein function.
Finally, this optimized cholesterol efflux protocol allowed us
to functionally study the main features of vectorial cholesterol
transport in cultured MEC. When the cholesterol efflux assay
was applied to MeBo cells in the Transwell® system, we were
able to show that the apoA-I/ABCA1 pathway mediates
cholesterol efflux from both the apical (milk-facing) and
basolateral (blood-facing) side. At steady state conditions, i.e.
in complete culture medium and the absence of hormonal
stimuli, cholesterol efflux appeared to be more accentuated at
the basolateral aspects of MeBo cells. Further studies have to
clarify whether pregnancy-related and/or lactogenic hormones
such as prolactin or hydrocortisone might modulate the extent
and direction of cholesterol transport in MEC. This will help to
determine if the apoA-I/ABCA1 complex acts predominantly as
cholesterol transport mechanism relevant for the milk
composition or rather as pathway in redirecting cholesterol
back into bloodstream.
Conclusions and Perspectives
The present study demonstrates the suitability of ex vivo
collected and frozen MG tissues in defining the binding kinetics
of 125I-apoA1 and 3H-cholesterol, and the applicability of those
ex vivo criteria to optimize the frequently used cholesterol efflux
cell culture model in terms of time and efficiency. Furthermore,
the results confirmed the relevance of the apoA-I/ABCA1
complex in cholesterol transport in the MG and showed
differences in apoA-I mediated efflux between the apical and
basolateral sides of MeBo cells at steady state conditions.
Additional studies are needed to explore a potential modulation
of vectorial cholesterol transport by pregnancy-related and
lactogenic hormones, and to identify the underlying intracellular
signaling processes associated with apoA-I/ABCA1 activities in
MEC. Together, this will help to better understand the
functional impact of the apoA-I/ABCA1 pathway in cholesterol
transport associated with milk formation during lactation.
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